August 11th 2025
NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.
Comorbidities in Borderline Personality Disorder
January 10th 2013Borderline personality disorder typically coexists with depression, anxiety, and substance abuse. Symptoms of these conditions may lead the clinician to miss the diagnosis of personality disorder entirely. Careful diagnosis of BPD and comorbid disorders is the first step.
Read More
Physician Well Being: Who Cares?
December 20th 2012The demands on physicians keep growing-they are not only responsible for assessment, diagnosis, and treatment, they are subject to all manner of related administrative and practice responsibilities. Not surprisingly, physicians are susceptible to burnout.
Read More
Suicide: Complexities and Treatment Challenges
December 14th 2012Patients with major depression or bipolar depression have a 20- to 26-fold increase of mortality rate over the general population. Suicidal behavior can be quite complex as well deadly. It should go without saying that psychotherapy is usually necessary in treating patients who have suicidal ideation or who have demonstrated such tendencies or actions. Frequently, it may be combined with medication and sometimes it is the treatment of choice without medication.
Read More
Deep Brain Stimulation: New Promise in Alzheimer Disease and Depression?
December 13th 2012The evolution of deep brain stimulation for various neuropsychiatric disorders results from advances in structural and functional brain imaging, increased understanding of neurocircuitry of the brain, and improvements in neurosurgical techniques and equipment.
Read More
Brief Screening Tools Can Improve Patient Care
November 29th 2012Medical colleagues routinely monitor patients with sphygmomanometers, peak flow meters, and glucometers. Similarly, psychiatrists can and should incorporate the use of screening tools to help with diagnosis and treatment management.
Read More
Atypical Depression in the 21st Century: Diagnostic and Treatment Issues
November 20th 2012Identification of atypical features is important in the treatment of depression for both treatment selection and prognosis, especially when initial measures prove ineffective. The concept of atypical depression has evolved over many years, and now it appears timely for a further revision.
Read More
Pediatric Major Depressive Disorder: Questions to Consider
November 16th 2012What are the options for treating major depressive disorder in children and adolescents? This case offers readers a chance to give their feedback and to interact with the authors, who will present teaching points based on your comments.
Read More
You Can’t Turn a Sow’s Ear Into a Silk Purse
November 14th 2012The DSM-5 leadership is trying to put a brave face on its badly failed first stage of field testing and has offered no excuse or explanation for canceling its second and most crucial quality control stage. This field testing fiasco erases whatever was left of the credibility of DSM-5 and APA.
Read More
Tips for Treating Comorbid Depression and Anxiety
October 9th 2012Comorbid depressive and anxiety disorders are commonly seen in both primary care and the specialty setting. Such comorbidity can present as major depression with subsyndromal anxiety symptoms or unipolar/bipolar depression with an anxiety disorder.
Read More
Are Psychiatric Disorders Inflammatory-Based Conditions?
A plethora of studies support the hypothesis that inflammation plays a role in the pathophysiology of major psychiatric disorders.
Read More
Irreversible Monoamine Oxidase Inhibitors Revisited
October 8th 2012Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.
Read More
Alcohol Disorders: Practical Tips From New Research
September 8th 2012In this review, we discuss the established medications as well as experimental therapeutic options that may emerge as future medications for alcohol intoxication, withdrawal, and/or long-term abstinence maintenance or harm-reduced drinking.
Read More